Table 2.
Comparison of the included interventions for OS: hazard ratio (95% CI). Each cell gives the effect of the column-defining intervention relative to the row-defining intervention
| FP | 0.981 ( 0.414, 2.389) | 0.987 ( 0.339, 3.079) | 1.035 ( 0.259, 4.316) | 1.031 ( 0.415, 2.497) | 0.79 ( 0.310, 2.059) | 0.74 ( 0.29, 1.90) | 1.058 ( 0.302, 3.693) | 0.732 ( 0.213, 2.655) | 0.928 ( 0.247, 3.376) |
|---|---|---|---|---|---|---|---|---|---|
| FP + LV* | 1.012 ( 0.531, 2.040) | 1.053 ( 0.359, 3.256) | 1.047 ( 0.299, 3.565) | 0.81 ( 0.228, 2.935) | 0.76 ( 0.21, 2.75) | 1.075 ( 0.438, 2.558) | 0.74 (0.31, 1.85) | 0.936 ( 0.193, 4.560) | |
| FP + LV + OXA | 1.043 ( 0.429, 2.518) | 1.034 ( 0.245, 4.178) | 0.79 ( 0.184, 3.309) | 0.748 ( 0.173, 3.154) | 1.061 ( 0.339, 3.146) | 0.737 ( 0.238, 2.280) | 0.920 ( 0.164, 5.169) | ||
| FP + LV + OXA + PEG | 0.993 ( 0.182, 5.175) | 0.760 ( 0.138, 4.144) | 0.721 ( 0.132, 3.904) | 1.027 ( 0.239, 4.130) | 0.713 ( 0.171, 2.998) | 0.876 ( 0.129, 5.870) | |||
| S1 + OXA^ | 0.772 ( 0.214, 2.822) | 0.726 ( 0.197, 2.708) | 1.022 ( 0.223, 4.678) | 0.717 ( 0.156, 3.492) | 0.891 ( 0.179, 4.455) | ||||
| CAPE + ruxolitinib | 0.943 ( 0.239, 3.501) | 1.336 ( 0.275, 6.423) | 0.931 ( 0.195, 4.401) | 1.167 ( 0.229, 5.819) | |||||
| IRINOTECAN + FP° | 1.405 ( 0.305, 6.781) | 0.987 ( 0.210, 4.744) | 1.225 ( 0.482, 3.074) | ||||||
| NALIRI | 0.701 ( 0.201, 2.473) | 0.881 ( 0.144, 5.266) | |||||||
| NALIRI + FP + LV | 1.246 ( 0.206, 7.622) | ||||||||
| Veliparib + IRINOTECAN + FP |
*, include also S1 + leucovorin doublet; OFF, oxaliplatin + 5Fluorouracil + folinic acid; °, include FOLFIRI and S1 + irinotecan; ^, S1 + oxaliplatin; italics identifies direct comparisons